Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
monovalent VEE VLP vaccine + aluminum hydroxide
- Development stage
- Unknown
- Lead developer
- Vaccine Research Center
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The monovalent VEE VLP vaccine + aluminum hydroxide is a recombinant virus-like particle (VLP) vaccine candidate designed to prevent infection by the Venezuelan Equine Encephalitis Virus (VEEV). The vaccine consists of VEEV structural proteins—specifically the capsid and the envelope glycoproteins E1 and E2—that self-assemble into non-infectious particles mimicking the native virus structure. These VLPs induce a potent neutralizing antibody response without the risks associated with live-attenuated or inactivated whole-virus vaccines. It is formulated with aluminum hydroxide (Alhydrogel) as an adjuvant to enhance its immunogenicity. Developed by the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), this candidate is intended for populations at risk of VEEV exposure, including laboratory workers, military personnel, and for biodefense applications.
- Other names
- VEEV-VLP vaccineVenezuelan Equine Encephalitis Virus-Like Particle vaccinemonovalent VEEV-VLP vaccine
02
Targets
HCV E2 (Hepatitis C virus envelope glycoprotein E2)Venezuelan equine encephalitis virus capsid proteinHCV E1 (Hepatitis C virus envelope glycoprotein E1)
Beyond the preview
Go deeper on monovalent VEE VLP vaccine + aluminum hydroxide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on monovalent VEE VLP vaccine + aluminum hydroxide.